mikey

$UFPI bull case: 30% drawdown pricing in a housing bust. Cyclical R&R/construction trough with recovery in progress. ~$4.59 EPS weighed down by lumber normalization, big-box destocking & volume pressure. With housing stabilization & buybacks, EPS $5.74+ by 2027. $108 target

@slapshotcapital flyer and habs haha, its been a rough few years

@midcapmikey Are you a Habs fan ?

Modelos & Noah Kahan album. She WILL be hearing from me this weekend.

@EverydayCap annual meeting is coming up in a few weeks, will be interesting to see management plan on addressing the ~$1B of 2026 refis in a higher interest environment

@midcapmikey Armoyan is loading up

$MRC.TO: • ~0.26x BV • ~7x earnings • ~$18B+ asset base vs ~$1.3B mkt cap You’re buying a levered, complex RE platform at a massive NAV discount. The catch? Controlled structure, weak governance, no clear catalyst. Value trap or multi-bagger? Could go either way lol.

$BRK.B $373B cash/t-bills + Apple/AXP/BAC fortress, funded by $176B float Abel inherits Buffett's float machine and cash and has been working in the background for years. A proven investor will present his playbook on May 2nd. Regardless, trains still run. Policies still pay

@petition skip the restructuring lawyer, these software shops are gonna need criminal lawyers

You’re gonna start seeing hedge funders and bankers with law degrees go back to big law. It’s a complete paradigm shift with $80mm/3-year pay packages.

@slapshotcapital I'm just here for the flyers vs penguins matchup in the first round

I’ll call it: Boston - San Antonio NBA Finals Tampa - Dallas Stanley Cup.

@rich_toad fee generation vs multiple/value generation

The buy-side's frustration with sell-side research is valid. Their understanding of why it's broken isn't.

@eastvillageguy deal sleds at home. short everything

$MOH bull case: 50% drawdown is pricing in permanent damage. Reality: Cyclical Medicaid trough with recovery in progress Current EPS of ~$5 weighed down by medicaid rates lag, contract ramp-up, and with more contracts in the pipeline, EPS should be $13+ by 2027 $200 Target

$ZTS bull case: Global #1 in animal health. ~40% EBITDA margins. $2B+ FCF/yr. Stock down ~25% in a year on a drug safety scare that regulators called "informational." Trades 20-25% below intrinsic value, management buybacks Pets still get sick. Owners still pay.